- Home
- MRSN
as 11-15-2024 4:00pm EST
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 230.0M | IPO Year: | 2017 |
| Target Price: | $6.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.22 - $6.28 | Next Earning Date: | 11-13-2024 |
| Revenue: | $34,837,000 | Revenue Growth: | -14.70% |
| Revenue Growth (this year): | -29.81% | Revenue Growth (next year): | 7.15% |
Stock Insider Trading Activity of Mersana Therapeutics Inc. (MRSN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lowinger Timothy B | MRSN | SVP, Chief Sci.&Tech. Officer | Oct 1 '24 | Sell | $1.98 | 13,687 | $27,150.08 | 241,240 | |
| Bala Mohan | MRSN | SVP, Chief Development Officer | Oct 1 '24 | Sell | $1.98 | 13,687 | $27,150.08 | 55,963 | |
| Mandelia Ashish | MRSN | VP, Chief Accounting Officer | Oct 1 '24 | Sell | $1.98 | 8,216 | $16,297.56 | 51,118 | |
| Carvajal Alejandra | MRSN | SVP, Chief Legal Officer | Oct 1 '24 | Sell | $1.98 | 13,687 | $27,150.08 | 69,314 | |
| DeSchuytner Brian | MRSN | SVP, COO & CFO | Oct 1 '24 | Sell | $1.98 | 13,687 | $27,150.08 | 94,824 | |
| Huber Martin H. Jr. | MRSN | President, CEO | Sep 11 '24 | Sell | $1.76 | 50,423 | $88,744.48 | 116,327 |
Latest Mersana Therapeutics Inc. News
MRSN Breaking Stock News: Dive into MRSN Ticker-Specific Updates for Smart Investing
GuruFocus.com
4 days ago
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
Thomson Reuters StreetEvents
4 days ago
Q3 2024 Mersana Therapeutics Inc Earnings Call
Zacks
4 days ago
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
4 days ago
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
GlobeNewswire
11 days ago
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
GuruFocus.com
a month ago
SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc
Simply Wall St.
3 months ago
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Zacks
3 months ago
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates
Compare MRSN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRSN Mersana Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.